NCT06606730 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06606730
Title	Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer (OPT-PEMBRO)
Acronym	OPT-PEMBRO
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	UNICANCER
Indications	triple-receptor negative breast cancer
Therapies	Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	FRA \| BEL

Facility	Status	City	State	Zip	Country	Details
Cliniques Universitaires Saint Luc Brussels	RECRUITING	Brussels		1200	Belgium	Details
Institut Gustave Roussy	RECRUITING	Villejuif		94805	France	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06606730Clinical Trial Detail